OOIR: Observatory of International Research

Papers

(The H4-Index of Diabetes Obesity & Metabolism is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Trends in pharmacological management of paediatric patients with type 2 diabetes from 2000 to 2023 in German‐speaking countries: Analysis based on the Diabetes Prospective Follow‐up Registry	635
Continuous glucose monitoring and all‐cause mortality in insulin‐using population with diabetes and cognitive impairment	248
Comparing clinical outcomes in patients with type 2 diabetes mellitus after ischaemic stroke: Sodium–glucose cotransporter 2 inhibitors users versus non‐users. A propensity score matching National Coh	153
Serum levels of the incretin‐like peptide 26RFa are diminished in women living with obesity and diabetes and restored after sleeve gastrectomy: Resul	147
Global deletion of G protein‐coupled receptor 55 impairs glucose homeostasis during obesity by reducing insulin secretion and β‐cell turnover	144
Normoalbuminuria—is it normal? The association of urinary albumin within the ‘normoalbuminuric’ range with adverse cardiovascular and mortality outcomes: A systematic review and meta‐analysis	129
Incidence of chronic kidney disease among adults with prediabetes in the CURE ‐ CKD registry, 2013	108
Concurrent SGLT2 inhibitor use in patients with type 2 diabetes hospitalised for high‐dose corticosteroid therapy: Mitigated iatrogenic hyperglycaemia	96
Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetes	96
Visceral fat mass dynamics in a 2‐year randomized STrength versus ENdurance training trial in people with obesity	86
Professional continuous glucose monitoring in patients with diabetes mellitus: A systematic review and meta‐analysis	86
Plasma fatty acid esters of hydroxy fatty acids and surrogate fatty acid esters of hydroxy fatty acids hydrolysis activity in children with or without obesity and in adults with or without coronary ar	85
Type 2 diabetes pharmacotherapy trends in high‐risk subgroups	79
	77
Effects of atrasentan on markers of liver function in patients with type 2 diabetes and chronic kidney disease	76
Issue Information	74
A prospective observational study to evaluate a possible relationship between vitamin K antagonist therapy and risk of peripheral arterial disease in patients with type 2 diabetes	74
Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐bli	72
Utility of serum β2‐microglobulin for prediction of kidney outcome among patients with biopsy‐proven diabetic nephropathy	63
Long‐term adherence to glucose‐lowering medications in adults with diabetes: A data linkage study	62
The effects of antihypertensive drugs on glucose metabolism	62
Anthropometric metabolic subtypes and health outcomes: A data‐driven cluster analysis	62
Front Cover	55
The benefit of dexamethasone in patients with COVID ‐19 infection is preserved in patients with diabetes	55
Long‐term effects of metformin on offspring health: A review of current evidence and future directions	54

Impact of sedentary behaviour on glucose concentration in people with type 1 diabetes	53
Response to letter from Du et al. regarding article ‘Sodium‐glucose cotransporter‐2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?’	53
Once‐weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis	53
GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity	53
Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, phase 3 trial	50
Correction to “Real‐world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus”	50
Superior benefits of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease: A cohort study	50
A review of the safety of sodium‐glucose co‐transporter‐2 inhibitors	49
Interventions to improve glycaemic control in people living with, and at risk of developing type 2 diabetes	48
Effect of haemodialysis on the pharmacokinetics and pharmacodynamics of evogliptin	47
Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c	46
Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study	46
Association patterns of ketone bodies with the risk of adverse outcomes according to diabetes status	45
A retrospective analysis of 24‐month real‐world glucose control for children and adolescents with type 1 diabetes using the MiniMed™ 670G insulin pum	45
Impact of social disadvantage on clinical and health care use indicators in adults with type 1 diabetes using insulin pumps in Ontario, Canada	45
Effects of GLP ‐1 receptor agonists on cognitive function in patients with type 2 diabetes: A systematic review and meta‐analysis based on randomized	44
Combined liraglutide and metformin therapy in overweight or obese women with polycystic ovary syndrome: A systematic review and meta‐analysis	43
Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic	43